Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer

뉴스 본문을 불러오고 있어요.

Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer | 웨이프 WAPE

Genmab Announced Sunday At ESMO, Updated Phase 2 Petosemtamab Plus Chemotherapy Data Showing 75% First-Line, 67% Second-Line Response Rates In Metastatic Colorectal Cancer

기사 요약

관련 종목

댓글 —